Home / Publications / CMS Next / ST Pharm establishes new medical testing and analysis...
  1. Protection and loyalty: securing valuable trade secrets
  2. Meet our expert: Maria Figueiredo, Partner, Portugal
  3. Meet our expert: Dalia Majumder-Russell, Partner, UK
  4. Digitalisation and innovation
  5. Contributing to climate-neutral transportation
  6. Investing in intelligent automation
  7. Advising on innovative digital project
  8. Supporting climate-resilient businesses
  9. Supercharged ESG: Getting control of the post-COVID agenda
  10. Meet our expert: Adriana Escobar, Partner, Colombia
  11. Meet our expert: Babita Ambekar, Partner, Singapore
  12. Meet our expert: Bridgett Majola, Partner, South Africa
  13. Meet our expert: Lillian Lofty, Partner, Kenya
  14. Meet our other experts
  15. After the pandemic
  16. Digital transformation & sustainability to help overcome COVID crisis
  17. Data and risk: challenges in an uncertain world
  18. Smart living: creating a framework for disruption and innovation
  19. Technology: a unifying force
  20. The green economy: identifying primary risks and key opportunities
  21. The true cost of ESG
  22. Developing markets
  23. Helping our clients grow
  24. Investing in new technologies
  25. Shaping the Energy Transition
  26. Supporting electromobility
  27. Transforming the short-term insurance industry in the East African market
  28. Advising on a EUR 1.1bn Bulgarian gas pipeline procurement
  29. ALPLA expands its global plastic recycling capabilities
  30. CMS advises on first ever European real estate transaction using blockchain
  31. CMS advises on ‘Train Maya’ rail project
  32. CMS helps the BBC launch the streaming service BritBox in the UK
  33. Commerz Real lands the largest deal in its history
  34. Helping Teyliom Hospitality’s expansion in Central and West Africa
  35. Online gambling grows as Gamesys is sold to JPJ Group
  36. Selling the Merkur offshore wind farm
  37. ST Pharm establishes new medical testing and analysis business line
  38. CMS expands in Norway
  39. One woman’s journey to advocating for fair global health
  40. Raising funds for a good cause
  41. CMS Academy adds participants through digital learning
  42. Lupl delivers transformative open industry platform for legal matters
  43. Heike Wagner on women in law

ST Pharm establishes new medical testing and analysis business line

Toby Grainger
CMS was able to seamlessly coordinate a cohesive and extremely responsive team working across different countries and time zones to ensure the transaction flowed and completed in an efficient manner.
Toby Grainger

ST Pharm Co. Ltd, a major Korean pharmaceuticals manufacturer, acquired a 70% stake in Swiss contract laboratory services and histopathology company AnaPath Services in November 2019. At the same time, AnaPath purchased a 100% share in Envigo CRS, a Spanish contract research organisation. The businesses will integrate under the AnaPath Research brand.

The synergies and strategic value of the acquisitions are extremely significant. The world-class research business capabilities of the Spanish operations, paired with the advanced laboratory and testing competences from AnaPath Services, enable ST Pharm to rapidly accelerate its new drug development and contract development and manufacturing (CDMO) ambitions. This is something that would have taken considerably longer through a domestic and organic approach.

Led by Singapore-based partner Toby Grainger, CMS teams in Singapore, Spain and Switzerland advised the acquirers on both transactions.

The deals posed a number of legal challenges. The CMS team in Spain, for example, had to navigate the local entity out of a statutory winding down process, directly negotiate with unionised employee representatives and coordinate an effective resolution to debt and capitalisation deficiencies. CMS was able to swiftly mobilise its employment expertise to ensure participation in meetings and negotiations was smooth and seamless. Beyond local issues, there was the negotiation of a technical services agreement, handled by the Singapore team. The negotiation was made more complex as the vendor counterparty had itself been recently sold to another US group and was hence reliant on its new parent delivering on the transitional services to a large extent (in particular, ensuring support for the completion of ongoing clinical trials).

According to Toby Grainger, “CMS was able to seamlessly coordinate a cohesive and extremely responsive team working across different countries and time zones to ensure the transaction flowed and completed in an efficient manner. The team’s familiarity with the relevant issues, turnaround on documentation and working ‘as one’, meant that expertise could be mobilised swiftly and effective resolutions presented to the client in a time-sensitive backdrop.”

Key contact

Toby Grainger
Managing Partner
Head of Corporate and Indonesian Desk, Singapore
Singapore
T +65 9837 8559